In summary, by integrating genome-wide, loss-of-function genetic screens with RNA sequencing and DNA methylation, we identified VRK1 as a selective vulnerability in CNS and PNS cancers with low VRK2 expression. This evidence concerns the gene VRK1 and paraneoplastic neurologic syndrome.